Literature DB >> 3680073

Ciprofloxacin therapy in cystic fibrosis.

J A Raeburn1, J R Govan, W M McCrae, A P Greening, P S Collier, M E Hodson, M C Goodchild.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3680073     DOI： 10.1093/jac/20.3.295

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  8 in total

Review 1.  Cystic fibrosis--an Indian perspective on recent advances in diagnosis and management.

Authors:  S K Kabra; M Kabra; M Ghosh; I C Verma
Journal:  Indian J Pediatr       Date:  1996 Mar-Apr       Impact factor: 1.967

2.  Development of resistance to ciprofloxacin in nutrient-rich and nutrient-limited growth conditions in vitro by Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  M I Ferguson; E M Scott; P S Collier
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

3.  Isolation of fluoroquinolone-resistant Escherichia coli and Klebsiella pneumoniae from an infected Hickman catheter.

Authors:  M López-Brea; T Alarcón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-05       Impact factor: 3.267

Review 4.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

5.  In vitro activity of sparfloxacin (AT-4140), a new quinolone agent, against invasive isolates from pediatric patients.

Authors:  J C Akaniro; H R Stutman; A G Arguedas; O M Vargas
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

Review 6.  Safety and efficacy of ciprofloxacin in paediatric patients--review.

Authors:  R Kubin
Journal:  Infection       Date:  1993 Nov-Dec       Impact factor: 3.553

Review 7.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

8.  Prophylactic co-trimoxazole versus norfloxacin in neutropenic children--perspective randomized study.

Authors:  M Cruciani; E Concia; A Navarra; L Perversi; F Bonetti; M Aricò; L Nespoli
Journal:  Infection       Date:  1989 Mar-Apr       Impact factor: 3.553
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.